TRIAZOLAM
Clinical safety rating: avoid
Positive evidence of fetus risks but benefits may outweigh risks in some cases
Triazolam is a benzodiazepine that binds to GABA-A receptors at the alpha-1 subunit, potentiating the inhibitory effects of GABA and increasing chloride ion influx, leading to neuronal hyperpolarization and sedation.
| Metabolism | Primarily metabolized by CYP3A4 to alpha-hydroxytriazolam (active) and 4-hydroxytriazolam (inactive), further conjugated to glucuronides. |
| Excretion | Primarily renal: approximately 80% as metabolites, less than 2% unchanged; biliary/fecal: minor (about 8-10%). |
| Half-life | 1.5-5.5 hours (mean 2-4 hours) in healthy adults; prolonged in hepatic cirrhosis and elderly. |
| Protein binding | 85-90%, primarily to serum albumin. |
| Volume of Distribution | 0.8-1.3 L/kg; indicates extensive tissue distribution and rapid redistribution from CNS. |
| Bioavailability | Oral: approximately 44% (range 25-65%) due to extensive first-pass metabolism. |
| Onset of Action | Oral: 15-30 minutes (full sedative effect). |
| Duration of Action | 1.5-3 hours for hypnotic effect; clinical duration short due to rapid redistribution and elimination. Avoid repeat dosing within same night. |
0.125-0.25 mg orally once daily at bedtime; maximum 0.5 mg/day.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment required; use with caution in severe impairment. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated. |
| Pediatric use | Not recommended for pediatric patients (safety and efficacy not established in children). |
| Geriatric use | Initial dose 0.125 mg orally at bedtime; may increase to 0.25 mg if needed. Avoid use due to increased risk of falls and cognitive impairment; limit to short-term use. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Strong CYP3A4 inhibitors are contraindicated due to risk of profound sedation Can cause anterograde amnesia and severe sedation.
| Breastfeeding | Triazolam is excreted into breast milk; the milk-to-plasma ratio (M/P) is approximately 0.2. Due to the potential for infant sedation, respiratory depression, and withdrawal symptoms, breastfeeding is generally not recommended during triazolam therapy. If use is necessary, monitor the infant for excessive drowsiness, poor feeding, and respiratory depression. |
| Teratogenic Risk | Triazolam is a benzodiazepine classified as Pregnancy Category X. In the first trimester, there is evidence of increased risk of congenital malformations, particularly cleft lip and palate, when used during early pregnancy. Use during the second and third trimesters may lead to fetal exposure and potential neonatal withdrawal symptoms, including hypotonia, respiratory depression, and floppy infant syndrome. There is also risk of neonatal sedation and withdrawal if used near term or during labor. Avoid use in pregnancy unless absolutely necessary for seizure disorders. |
■ FDA Black Box Warning
Triazolam has a boxed warning for concomitant use with opioids due to risk of profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients without alternative treatment options.
| Common Effects | Sedation |
| Serious Effects |
["Hypersensitivity to triazolam or other benzodiazepines","Concurrent use with ketoconazole, itraconazole, or other potent CYP3A4 inhibitors","Pregnancy (risk of fetal harm)","Acute narrow-angle glaucoma","Severe hepatic impairment"]
| Precautions | ["Risk of CNS depression, impaired motor function, and amnesia","Anterograde amnesia may occur","Worsening of depression or suicidal thoughts","Respiratory depression in patients with compromised respiratory function","Dependence and withdrawal syndrome with prolonged use","Paradoxical reactions (e.g., agitation, hallucinations)","Elderly patients at increased risk of falls and cognitive impairment"] |
Loading safety data…
| Fetal Monitoring | Maternal: Monitor for excessive sedation, dizziness, ataxia, and cognitive impairment. Assess for signs of dependence or withdrawal. Fetal: If exposure occurs during pregnancy, monitor fetal growth and development; consider detailed ultrasound for structural anomalies if first trimester exposure. Neonatal: Observe for symptoms of hypotonia, respiratory depression, and withdrawal (e.g., irritability, tremors, hypertonia) at birth. |
| Fertility Effects | Triazolam may affect fertility in males and females. In animal studies, high doses caused decreased fertility and impaired reproductive performance. In humans, benzodiazepines may disrupt menstrual cyclicity and spermatogenesis, but clinical data are limited. Use may interfere with hormonal balance and ovulation. |